We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Notice for pembrolizumab (Merck Sharp & Dohme (Australia) Pty Ltd)
Active ingredients
pembrolizumab
Date of review outcome
Lapse date
Type
Priority review
Indication
As first-line treatment of patients with unresectable or metastatic mirosatellite instability high (MSI-H) or mismatch repair deficient (dMMR) cancer
Therapeutic area
Oncology